CD19 and acute lymphoblastic leukemia: Blinatumomab, a bispecific T‐Cell engager (BiTE) construct that links CD19+ malignant B cells to CD3+ T cells, has been approved by the US Food and Drug Administration for the treatment of adult and childhood relapsed/refractory (R/R) B‐ALL and persistent MRD in B‐ALL.